What If Semaglutide Doesn't Work? Refund Policies & Risk-Free Options
Worried semaglutide won't work for you? This guide covers what happens if GLP-1 doesn't produce results, what refund policies actually exist, why some patients don't respond, and how to reduce your financial risk.
Written by Trimi Medical Team. Medically reviewed by Trimi Medical Review Board. This article is for informational purposes only.
More on Patient Journey
"What if it doesn't work?" is a legitimate concern before starting any new medication — especially one that costs $99–$125/month for a compounded version, or dramatically more for brand-name.
This guide answers that question honestly: what the clinical data says about response rates, why some patients don't respond, what refund policies typically look like for compounded GLP-1 programs, what to do if semaglutide isn't working, and how to minimize your financial risk.
What the Clinical Evidence Says About Response Rates
Semaglutide is one of the most effective weight-loss medications ever studied. The clinical question is not whether it works for most people — it clearly does — but what happens in the minority of patients who don't see the expected response.
Response statistics from STEP trials
| Outcome threshold | % of semaglutide patients achieving this (STEP 1) | % of placebo patients |
|---|---|---|
| ≥ 5% weight loss | 86.4% | 31.5% |
| ≥ 10% weight loss | 69.1% | 12.0% |
| ≥ 15% weight loss | 50.5% | 4.9% |
| ≥ 20% weight loss | 32.0% | 1.7% |
These are 68-week data at the full 2.4mg maintenance dose. Note that approximately 86% of patients on semaglutide lost at least 5% of body weight — meaning roughly 14% of patients at full dose did not achieve even this threshold. That minority exists, and it is worth understanding what drives it.
Why Semaglutide Doesn't Work for Some Patients
When semaglutide produces less-than-expected results, the cause usually fits into one of several categories. Understanding which applies to your situation determines what to do next.
Insufficient dose or duration — the most common reason
The Wegovy dose titration schedule takes 16–20 weeks to reach the 2.4mg maintenance dose. Patients who stop or stay at starting doses due to side effects never experience the full therapeutic effect. Similarly, assessing the medication at 8 weeks while still at 0.5mg is not an adequate trial. Many "non-responders" actually did not complete dose titration.
Dietary compensation
GLP-1 medications reduce appetite but do not prevent eating. Some patients consciously or unconsciously compensate for reduced hunger by selecting higher-calorie foods or eating more frequently. The result is that caloric deficit never exceeds expenditure, and weight stays flat. This is behavioral, not a drug failure.
Underlying metabolic factors
Hypothyroidism, Cushing's syndrome, severe insulin resistance, and certain medications (antipsychotics, steroids, some antidepressants) can significantly blunt GLP-1 response. If you are on medications known to cause weight gain or have an undiagnosed endocrine condition, addressing those factors matters alongside GLP-1 treatment.
True primary non-response (rare)
A small minority of patients — estimated at 5–10% — appear to have reduced GLP-1 receptor sensitivity or other pharmacogenomic factors that limit response even at full dose. For these patients, tirzepatide (which adds the GIP receptor pathway) often produces meaningful results even when semaglutide did not.
Refund Policies for Compounded GLP-1 Programs
Understanding refund policies before you start is part of risk management. Here is the honest picture of what most telehealth GLP-1 programs offer.
What typically can and cannot be refunded
- Provider/evaluation fee: If you pay a separate evaluation fee and the provider determines you are not eligible for GLP-1 treatment, most programs refund the medication cost. The evaluation itself may or may not be refundable.
- Unshipped medication: If your medication has not yet shipped (typically the first 1–2 business days after approval), cancellation is straightforward and a refund is usually available.
- Prepared and shipped medication: Once compounded injectable medication has been prepared and shipped, it cannot be returned — both for patient safety (sterility cannot be verified on a returned product) and because the compounding was done specifically for your prescription. This is standard practice across compounding pharmacy programs.
- Outcome-based refunds (non-response): Most programs do not offer refunds based on individual non-response because: (1) medication was legitimately prepared to specification, (2) non-response may be dose/duration related rather than a program failure, and (3) outcomes depend on patient factors outside the provider's control. Some programs offer partial credits toward switching to tirzepatide.
Trimi refund policy: For current Trimi refund terms, visit trytrimi.com/terms or contact support@trytrimi.com directly. Terms are reviewed periodically and current details on the website supersede anything summarized here.
How to Minimize Financial Risk Before Starting
The best approach to managing the "what if it doesn't work" risk is financial structure, not refund guarantees. Here is how to minimize exposure:
- Start with a single month's supply — at $99/month for compounded semaglutide, a one-month trial costs less than a single specialist co-pay plus prescription
- Choose a month-to-month program with no long-term commitment — avoid programs that require 3-month or 6-month prepayment
- Verify the provider's contact and support model — can you reach them if side effects require dose adjustment?
- Understand the cancellation window — how much notice is needed to cancel before the next billing cycle?
- Start at the dose titration designed for tolerability — do not rush escalation, which increases the risk of stopping early due to side effects
Trimi operates on a monthly subscription model with no long-term commitment required. You can cancel before the next refill cycle if you decide not to continue.
If Semaglutide Isn't Producing Results: A Step-by-Step Evaluation
Before concluding that semaglutide is not working, work through this checklist with your provider:
- 1
Verify you have reached maintenance dose
Are you at 2.4mg/week? If you are still at 0.5mg or 1mg due to side effects or slow titration, you have not yet had an adequate clinical trial. Discuss dose escalation options with your provider.
- 2
Verify treatment duration
Have you been at maintenance dose for at least 12 weeks? Full response takes time. Most weight loss occurs during months 3–6 at maintenance dose.
- 3
Review dietary patterns honestly
Are you eating significantly more volume, more frequently, or higher-calorie foods since starting? GLP-1 medications reduce appetite signaling but do not override conscious food choices.
- 4
Review other medications
Are you on antipsychotics, steroids, certain antidepressants, or other medications known to cause weight gain? These can significantly offset GLP-1 benefits.
- 5
Consider thyroid and metabolic workup
If you have not had recent thyroid function tests, fasting glucose, and insulin levels, ask your provider whether these are warranted.
- 6
Discuss switching to tirzepatide
If you have completed an adequate semaglutide trial (maintenance dose, 12+ weeks) without sufficient response, tirzepatide is the most evidence-supported next step. Trimi offers compounded tirzepatide at $125/month.
Managing Side Effects: When to Adjust vs. When to Stop
Side effects — primarily nausea, vomiting, and GI discomfort — are the most common reason patients stop semaglutide prematurely. Most of these are dose-related and resolve with slower titration. Here is how to approach them:
| Side effect | Typical timing | What to do |
|---|---|---|
| Nausea (mild–moderate) | First 1–3 days after each dose increase | Eat smaller meals, avoid fatty foods, stay hydrated — usually resolves within a week |
| Persistent nausea at current dose | More than 2 weeks after dose increase | Contact provider — consider holding dose increase or stepping down one level |
| Vomiting | Usually during initial escalation | Slower titration — do not escalate until tolerability is established at current dose |
| Severe abdominal pain | Any time | Stop medication, seek emergency evaluation (rule out pancreatitis), contact provider immediately |
| Constipation | Ongoing — related to slowed gastric emptying | Increase fluid intake, fiber, gentle physical activity — discuss with provider if persistent |
The goal is to find the dose you tolerate well and gradually work up to the maintenance dose — not to rush escalation and then stop due to side effects. Your Trimi provider is available to support this process.
Switching to Tirzepatide: The Main Alternative
For patients who complete a genuine semaglutide trial and see insufficient results, tirzepatide is the most evidence-supported alternative within the GLP-1 class. As a dual GIP/GLP-1 receptor agonist, tirzepatide produces greater average weight loss than semaglutide in head-to-head comparisons:
- SURMOUNT-1: average 20.9% body weight loss at 15mg tirzepatide over 72 weeks
- SURPASS-2: tirzepatide produced significantly greater A1C reduction and weight loss than semaglutide 1mg in head-to-head trial
- Some semaglutide partial-responders see meaningfully better results on tirzepatide due to the additional GIP mechanism
Compounded tirzepatide is available through Trimi at $125/month — only $26 more per month than compounded semaglutide. For patients who want to try the stronger option from the start, it is also available as a first-line choice.
Setting Realistic Expectations
Managing expectations before starting reduces the chance of premature discontinuation. Key clinical facts every patient should know:
- The STEP 1 trial average of 14.9% weight loss was at 68 weeks — most patients see gradual, sustained loss, not rapid transformation
- Initial weeks are spent on low starting doses that produce limited weight loss — do not judge response at week 4
- Weight regain after stopping is well-documented — STEP 4 showed patients regained ~2/3 of lost weight within a year of stopping. GLP-1 is a long-term treatment
- Plateau periods are normal — the body adjusts metabolic rate during weight loss, causing temporary plateaus
- The medication reduces appetite; sustained weight loss requires acting on that reduced appetite through diet choices
For a full understanding of what to expect over the course of treatment, read does compounded semaglutide work as well as Ozempic?
Frequently Asked Questions
What happens if semaglutide doesn't work for me?
Semaglutide has a meaningful response rate — clinical trials show 80–90% of patients lose at least 5% of body weight over 68 weeks at the 2.4mg maintenance dose. For the minority who don't see adequate response, the most common explanations are insufficient dose escalation, inadequate treatment duration (most patients need 12–16 weeks at maintenance dose to see full response), or underlying metabolic factors. If semaglutide truly isn't working after an adequate trial at full dose, switching to tirzepatide is the most common clinical next step.
Does Trimi offer a refund if semaglutide doesn't work?
Trimi's refund policy should be reviewed directly on the Trimi website for current terms, as policies can change. Generally speaking, compounded medication that has been prepared and shipped cannot be returned for safety reasons. Most telehealth GLP-1 providers do not offer outcome-based refunds — they offer refunds for specific program failures (medication not delivered, provider error, etc.) rather than for individual non-response. The best risk-reduction strategy is starting with a single month's supply before committing to a longer program.
How long should I try semaglutide before concluding it doesn't work?
The clinical guideline is to reach the maintenance dose (2.4mg for semaglutide, as per the Wegovy label) and continue at that dose for at least 12–16 weeks before evaluating full response. Most patients do not reach maintenance dose until week 16–20 of treatment due to gradual titration. Assessing response at weeks 4–8 (while still on starting dose) is premature. Full response evaluation should happen at approximately weeks 28–32.
Why doesn't semaglutide work for some people?
GLP-1 non-response can have several causes: inadequate dose (never reaching or tolerating the maintenance dose), insufficient treatment duration, significant dietary compensation (eating more calories in response to reduced appetite), underlying conditions affecting response (severe insulin resistance, specific genetic factors), or tolerance development. True primary non-response — where the drug simply doesn't suppress appetite even at full dose — is rare (estimated under 10% of patients).
Is tirzepatide a better option if semaglutide didn't work?
Yes. Tirzepatide (dual GIP/GLP-1 agonist) produces greater average weight loss than semaglutide in trials — approximately 20.9% vs. 14.9% at highest doses. Some semaglutide partial-responders see meaningfully better results on tirzepatide due to the additional GIP mechanism. Trimi offers compounded tirzepatide at $125/month as a direct upgrade option.
Can I stop semaglutide if I experience intolerable side effects?
Yes, and stopping is always an option. Semaglutide side effects — primarily nausea, vomiting, and GI discomfort — are most pronounced during dose escalation and typically improve with time. Many patients who stop due to side effects can restart at a lower dose and titrate more slowly. If side effects are severe or persistent at low doses, your provider can help you evaluate whether continuing makes sense or whether a different approach is more appropriate.
How do I minimize financial risk when starting semaglutide?
The main risk-reduction strategies: start with a single month's supply rather than purchasing multiple months at once, choose a provider with transparent pricing and no long-term commitments, ensure your provider is available to support dose adjustments if side effects occur, and understand the cancellation/refund terms before ordering. At $99/month for compounded semaglutide through Trimi, the financial exposure for a one-month trial is lower than the cost of most in-person specialist visits.
Related Reading
Sources & References
- STEP 1 trial: Wilding JPH et al. Once-Weekly Semaglutide. NEJM 2021;384:989–1002.
- STEP 4 trial: Rubino D et al. Continued semaglutide vs. withdrawal. JAMA 2021;325:1414–1425.
- SURMOUNT-1 trial: Jastreboff AM et al. Tirzepatide for Obesity. NEJM 2022;387:205–216.
- SURPASS-2 trial: Frías JP et al. Tirzepatide versus semaglutide. NEJM 2021;385:503–515.
- FDA prescribing information for Wegovy.
Medical Disclaimer: This content is for informational purposes only. Individual results with semaglutide or tirzepatide vary. Refund policies described are general summaries — verify current Trimi terms at trytrimi.com. Consult a licensed healthcare provider before making any medication decisions.